Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trilaciclib myeloprotection study in induction chemotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2400087929Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in nasopharyngeal carcinoma (NPC), sponsored by First Hospital of China Medical University. Primary endpoint: Occurrence of severe neutropenia. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400087929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087929.